P
Peter Crome
Researcher at University College London
Publications - 95
Citations - 3851
Peter Crome is an academic researcher from University College London. The author has contributed to research in topics: Population & Stroke. The author has an hindex of 28, co-authored 93 publications receiving 3573 citations. Previous affiliations of Peter Crome include Keele University & North Staffordshire Combined Healthcare NHS Trust.
Papers
More filters
Journal ArticleDOI
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
C Courtney,D Farrell,Richard Gray,Robert Kerrin Hills,Lloyd Lynch,E Sellwood,S Edwards,Wendy Hardyman,James Raftery,Peter Crome,Corinne Lendon,H Shaw,Peter Bentham +12 more
TL;DR: Donepezil is not cost effective, with benefits below minimally relevant thresholds, and more effective treatments than cholinesterase inhibitors are needed for Alzheimer's disease.
Journal ArticleDOI
The National Service Framework for Older People: England's approach to ending age discrimination in services and therapeutics.
TL;DR: Successfully combating age discrimination is likely to require a regulatory framework, continued monitoring, tackling indirect forms of discrimination, as well as embedding antidiscrimination policies in all facets of health education.
Journal ArticleDOI
The persistent exclusion of older patients from ongoing clinical trials regarding heart failure.
Antonio Cherubini,J. Oristrell,Xavier Pla,Carmelinda Ruggiero,Roberta Ferretti,Germán Diestre,A. Mark Clarfield,Peter Crome,Cees M.P.M. Hertogh,Vita Lesauskaite,Gabriel Ioan Prada,Katarzyna Szczerbińska,Eva Topinkova,Judith Sinclair-Cohen,David L. Edbrooke,Gary H. Mills +15 more
TL;DR: Despite the recommendations of national and international regulatory agencies, exclusion of older individuals from ongoing trials regarding heart failure continues to be widespread.
Journal ArticleDOI
Clinical pharmacokinetic considerations in the elderly. An update.
S. Dawling,Peter Crome +1 more
TL;DR: Methods for individualisation of dosage regimens and the use of sustained-release formulations in the elderly are discussed, which may help improve compliance and knowledge of the pharmacokinetics of a drug helps determine which approach will be most beneficial.
Journal ArticleDOI
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.
TL;DR: Although aspirin is commonly used in dementia, in patients with typical AD 2 years of treatment with low-dose aspirin has no worthwhile benefit and increases the risk of serious bleeds.